DNALC Blogs » Medicines

Trying to unlock a new door…..

Jermel Watkins — Mon, 28 Nov 2011 21:59:10 +0000

How is drug development moving along? Well, this is a very good question for we are still plagued by some elusive diseases, cancer for example. There have been many drugs developed targeting proteins involved in disease states some of which have proven to be quite effective. However today the steam engine for identifying drug targets to proteins involved in disease is becoming ever more difficult.
Apparently over the past decade or so, the number of new drugs targeted toward disease has declined. This is primarily due to the fact that developing new medicine has become more difficult to do. It turns out that this is partly because we have sifted through all the ideal proteins that can be targeted by a drug. The remaining proteins are not ideal for developing a targeted drug. These proteins dawn small cavities or binding pockets and are relatively flat allowing for little to no interaction with a drug target. Its been said that 15% of proteins can be targeted by drugs. The percent of proteins that modify disease is 10 to 15 %. In order to alleviate this problem scientist have acquired the help of computer modeling to more thoroughly identify and test favorable small molecules that can block the activity of these undruggable protein populations related to disease. Dr. Stockwell an Associate professor at Columbia University, has attempted computer modeling and has come across compounds to target a class of E3 ligases, which are characteristically undruggable, and involved in just about every disease. Of these compounds one in particularly was a potent inhibitor. Dr. Stockwell will be publishing his findings in the next few months on the efficacy of the inhibitor. If it proves worthy this new drug will have an impact on cancer and neurodegenerative disease.

How can I prolong health? Hmmm…..

Jermel Watkins — Sat, 07 Nov 2009 00:33:03 +0000

Having an edge on the stock market can allow one to make hundreds, thousands or even millions of dollars. But rarely do we think of having an edge on life. Since the sequencing of the human genome our understanding of human genes and their interaction has grown. Geneticists now have the capability to analyze genetic make-ups, and elucidate what genetic patterns will evolve into certain conditions or disease states.

Any individual has a unique genetic profile different from that of another person. Contained within these differences are unique genetic variations that may make a person more susceptible to diseases such as cancer and diabetes. There are genetic profiling centers that can assist you in identifying your genetic variations. With this information you and your physician can watch your health where it is at risk to becoming a problem and mold a life style toward prolonged health. In order to decrease the impact of a possible problem, it is important that you’re analysis be broad-spectrum and precise. It will be of great interest to identify the premier centers for analysis of genetic variants. Be curious and talk with your physician about the resources that will give you the edge in enhancing your quality of life.

Medicine or Poison? It’s in Your Genes, duh…

Uwe Hilgert — Thu, 24 Sep 2009 20:48:05 +0000

As the ongoing deciphering of the human genome provides us with more and more insights about our predisposition for diseases and genetic disorders, (see Your Genes Your Health for examples) I am equally, if not more astounded by what it tells us about our ability to utilize medicines to counteract diseases.

Just recently, a group of researchers at the University of Maryland School of Medicine have identified a variant of a gene that is believed to play a major role in determining why people do not respond to a popular anti-clotting medication. This gene variant, carried by as many as a third of the general population can put patients at increased risk for subsequent heart attacks, strokes and other serious cardiovascular problems. The interesting thing is, that this increased risk is not due to patients genetic predisposition for these disorders, but because it renders their medication ineffective.

Medicines that we introduce into our bodies often require one or several important mechanisms to unfold their intended effects: they may have to be actively transported into our cells, biochemically altered and thereby activated, or they may require deactivation and/or removal in order to not do more harm then good. Any of these processes may involve proteins on one level or another and, therefore, depend on genes. Thus, as we have maps that indicate the loci associated with genetic disorders (visit Tour > genome spots in DNA Interactive), we will soon have maps that tell us where to look if we wish to know our predisposition to the medications we use to cure ailments: whether they will do us any good, are totally useless or, in a worst case scenario, can even harm us.